Body composition and psychological improvement in healthy premenopausal women assuming the oral contraceptive containing micronized estradiol (E2) and nomegestrol acetate (NOMAC)

References

• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577–82.
   PubMed Web of Science ®Google Scholar
• Larsson G, Blohm F, Sundell G, et al. A longitudinal study of birth control and pregnancy outcome among women in a Swedish population. Contraception 1997;56:9–16.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Perini D, Fornaciari L, et al. Discontinuation of modern hormonal contraceptives: an Italian survey. Eur J Contracept Reprod Health Care 2016;21:449–54.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Liew J, Garland KA. Depression associated with combined oral contraceptives – a pilot study. Aust Fam Physician 2005;34:990
   PubMedGoogle Scholar
• Fedor-Freybergh P, Hjelmqvist M, Zador G. Psychodiagnostic follow-up of Neovletta – a new low dose oral contraceptive. Acta Obstet Gynecol Scand Suppl 1976;54:77–82.
   PubMedGoogle Scholar
• Borgstrom A, Odlind V, Ekselius L, Sundstrom-Poromaa I. Adverse mood effects of combined oral contraceptives in relation to personality traits. Eur J Obstet Gynecol Reprod Biol 2008;141:127–30.
   PubMed Web of Science ®Google Scholar
• Poromaa IS, Segebladh B. Adverse mood symptoms with oral contraceptives. Acta Obstet Gynecol Scand 2012;91:420–7.
   PubMed Web of Science ®Google Scholar
• Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. Eur J Contracept Reprod Health Care 2015;20:329–43.
   PubMed Web of Science ®Google Scholar
• Grandi G, Xholli A, Napolitano A, et al. Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol. Contraception 2014;90:529–34.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531–9.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Buhling KJ. Why use of dienogest for the first contraceptive pill with estradiol? Gynecol Endocrinol 2009;26:109–13.
   Web of Science ®Google Scholar
• Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 2010;70:541–59.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46:S7–S16.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Chassard D, Ochsenbein E, et al. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study. Eur J Contracept Reprod Health Care 2011;16:76–84.
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Serfaty D, Chabbert-Buffet N, et al. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod 2011;26:1338–47.
   PubMed Web of Science ®Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011;16:430–43.
   PubMed Web of Science ®Google Scholar
• Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444–57.
   PubMed Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560–7.
   PubMed Web of Science ®Google Scholar
• Westhoff C, Kaunitz AM, Korver T, et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial. Obstet Gynecol 2012;119:989–99.
   PubMed Web of Science ®Google Scholar
• Witjes H, Creinin MD, Sundström-Poromaa I, et al. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol an drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care 2015;20:296–307.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, De Toni A, Caretto S, et al. Cyclic progestin administration increases energy expenditure and decreases body fat mass in perimenopausal women. Menopause 2006;13:197–201.
   PubMed Web of Science ®Google Scholar
• Lenzi E, Nicola Pluchino N, Begliuomini S, et al. Effects of nomegestrol acetate administration on central and peripheral beta-endorphin and allopregnanolone in ovx rats. J Steroid Biochem Mol Biol 2008;110:67–75.
   PubMed Web of Science ®Google Scholar
• Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis – part II: utilization in clinical practice. Clin Nutr 2004;23:1430–53.
   PubMed Web of Science ®Google Scholar
• Martinoli R, Mohamed EI, Maiolo C, et al. Total body fluid estimation using bioelectrical impedance: a meta-analysis of the data available in the literature. Acta Diabetol 2003;40:S203–6.
   PubMed Web of Science ®Google Scholar
• Gudivaka R, Schoeller DA, Kushner RF, Bolt MJ. Single- and multifrequency models for bioelectrical impedance analysis of body water compartments. J Appl Physiol 1999;87:1087–96.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Lello S, Lazzarini V, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 2007;75:199–203.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Lipman RS, Covi L. SCL-90: and outpatient psychiatric rating scale: preliminary report. ECDEU assessment manual. DHEW publication. Washington DC: U.S. Government Printing Office; 1976:313–331.
   Google Scholar
• Grandi G, Piacenti I, Volpe A, Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol 2014;30:676–80.
   PubMed Web of Science ®Google Scholar
• Paoletti AM, Lello S, Fratta S, et al. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol. Fertil Steril 2004;81:645–51.
   PubMed Web of Science ®Google Scholar
• Pluchino N, Lenzi E, Merlini S, et al. Selective effect of chlormadinone acetate on brain allopregnanolone and opioids content. Contraception 2009;80:53–62.
   PubMed Web of Science ®Google Scholar